Skip to main content
[Preprint]. 2023 Oct 9:2023.10.09.561507. [Version 1] doi: 10.1101/2023.10.09.561507

Figure 2.

Figure 2.

Chemical structures of three TYK2-specific allosteric inhibitors (BMS-986165/Deucravacitinib; BMS-986202; TAK-279) in advanced stages of clinic trials or Food and Drug Administration (FDA)-approved for some diseases (i.e. psoriasis) (top) and one selected conformational structure for each inhibitor (bottom).